Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma

Neuro-Oncology

Volumn 11, Issue 6, 2009, Pages 842-852

  Pirzkall, Andrea ^a,b   McGue, Colleen ^a   Saraswathy, Suja ^a   Cha, Soonmee ^a   Liu, Raymond ^a   Vandenberg, Scott ^a   Lamborn, Kathleen R ^a   Berger, Mitchel S ^a   Chang, Susan M ^a   Nelson, Sarah J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain glioma; Extent of resection; GBM; Glioblastoma; MRI; Tumor growth

Indexed keywords

CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CARMUSTINE; CELECOXIB; CHOLINE; ERLOTINIB; ISOTRETINOIN; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TIPIFARNIB;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSTOPERATIVE PERIOD; SURGICAL INJURY; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; BRAIN MAPPING; BRAIN NEOPLASMS; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PREOPERATIVE CARE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; UBIQUITIN-PROTEIN LIGASES;

EID: 69249138301     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2009-005     Document Type: Article

References (28)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
2. Surawicz TS, Davis F, Freels S, et al. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol. 1998;40:151-160.
3. Wrensch M, Minn Y, Chew T, et al. epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncology. 2002;4:278-299.
4. Scott JN, Rewcastle NB, Brasher PM, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol. 1999;46:183-188.
5. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer. 1987;59:1617-1625.
6. Albert FK, Forsting M, Sartor K, et al. early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994;34:45-61.
7. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190-198.
8. Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al. Prognostic signifi-cance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery. 1994;34:674-679.
9. Reavey-Cantwell JF, Haroun RI, Zahurak M, et al. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol. 2001;55: 195-204.
10. Hegi Me, Diserens AC, Gorlia T, et al. MGMT gene silencing and bene-fit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
11. Henegar MM, Moran CJ, Silbergeld DL. early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg. 1996;84:174-179.
12. Cairncross JG, Pexman JH, Rathbone MP, et al. Postoperative contrast enhancement in patients with brain tumor. Ann Neurol. 1985;17:570-572.
13. Forsting M, Albert FK, Kunze S, et al. extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. AJNR Am J Neuroradiol. 1993;14:77-87.
14. Smith JS, Cha S, Mayo MC, et al. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg. 2005;103:428-438.
15. Ulmer S, Braga TA, Barker FG 2nd, et al. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology. 2006;67:1668-1670.
16. Daumas-Duport C, Beuvon F, Varlet P, et al. [Gliomas: WHO and Sainte-Anne Hospital classifications] [in French]. Ann Pathol. 2000;20: 413-428.
17. Nelson SJ, Nalbandian AB, Proctor e, et al. Registration of images from sequential MR studies of the brain. J Magn Reson Imaging. 1994;4: 877-883.
18. Lupo JM, Cha S, Chang SM, et al. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol. 2005;26:1446-1454.
19. Tran TK, Vigneron DB, Sailasuta N, et al. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med. 2000;43:23-33.
20. Star-Lack J, Spielman D, Adalsteinsson e, et al. In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid sing lets at 1.5 T using PReSS excitation with applications to the study of brain and head and neck tumors. J Magn Reson. 1998;133:243-254.
21. Nelson SJ, Day MR, Buffone PJ, et al. Alignment of volume MR images and high resolution [18F]fluorodeoxyglucose PeT images for the evaluation of patients with brain tumors. J Comput Assist Tomogr. 1997;21:183-191.
22. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med. 2001;46:228-239.
23. McKnight TR, Noworolski SM, Vigneron DB, et al. An automated technique for the quantitative assessment of three-dimensional-MRSI data from patients with glioma. J Magn Reson Imaging. 2001;13:167-177.
24. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-5.
25. Saraswathy S, Crawford F, Lamborn K, et al. evaluation of pretreatment MR markers that predict survival in patients with newly diagnosed GBM.
26. Walker MD, Strike TA, Sheline Ge. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5:1725-1731.
27. Pennington C, Kilbride L, Grant R, et al. A pilot study of brain tumour growth between radiotherapy planning and delivery. Clin Oncol (R Coll Radiol). 2006;18:104-108.
28. Pirzkall A, Li X, Oh J, et al. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys. 2004;59:126-137.